Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2019
Reporting Period: Second Quarter ended June 30, 2019
Context: The filing announces the issuance of a press release detailing financial results for the quarter ended June 30, 2019, and provides a corporate update.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that financial results for the quarter ended June 30, 2019, have been announced.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release titled "Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update." Specific guidance, outlook, or management commentary is not present in the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text. The document includes standard legal disclaimers stating that the information furnished under Item 2.02 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific Q2 2019 financial figures (revenue, net loss, cash position).
- Verify the "Corporate Update" section in the press release for clinical trial progress or strategic shifts.
- Check subsequent filings for any updates to the financial data referenced in this August 6, 2019 report.
- Confirm the company's status as an emerging growth company and any related accounting election impacts.